feralridge3 said:should I be worried? 🤔
The MRI results look fine—she’s already seen the neurosurgeon, the neurologist, and most recently an oncologist who confirmed there are no signs of tumor recurrence—but...
spectroscopy shows elevated choline levels relative to NAA. They’re requesting a follow-up brain MRI with spectroscopy. If the spectroscopic findings come back positive, they would recommend chemotherapy following a VCR/CCNU regimen.
😕
The real challenge when performing MRIs on patients who have undergone brain tumor surgery—especially if that area was subsequently treated with radiation—is distinguishing between post-operative changes, radiation-induced effects, and an actual recurrence (a new tumor forming in the same spot) or residual tumor tissue.
When things are unclear, doctors turn to MR spectroscopy. It isn't just a standard scan; instead, it focuses on a specific target area—like a suspicious zone—to measure certain metabolites and compare them against healthy tissue.
In fact, MR spectroscopy has evolved specifically to evaluate these types of brain changes. There are several standard metabolites measured, and while their concentrations matter, the ratios between them are often even more critical in determining whether we are looking at healthy tissue or tumor cells.
One such metabolite is NAA, which serves as a marker for healthy neurons. A drop in NAA can signal neuron loss due to a tumor, though it can also decrease as a result of radiation therapy.
Choline, on the other hand, is a marker for cell membranes. Its concentration spikes when cells are multiplying rapidly—as is the case with fast-growing tumors—so an increase often points toward a recurrence.
Another important metabolite typically measured is creatine, which acts as an indicator of cellular metabolism levels.
There are others, of course, but they are generally less significant in tumor cases.
Ultimately, specialists examine the ratios of these various concentrations to try and draw a meaningful conclusion.
To make matters more complicated—and it certainly isn't simple—this type of imaging is technically demanding and can be influenced by many different variables. Furthermore, there aren't "absolute" values to use as a universal benchmark, so even after spectroscopy, the results can sometimes remain ambiguous.
In this particular case, I suspect the findings unfortunately point toward a probable recurrence—though, I should note, the rise in choline and the dip in NAA aren't quite extreme enough yet to be stated with absolute certainty.
That is likely why they are requesting a repeat brain MRI and spectroscopy after a set period; if the choline continues to climb, it would confirm a recurrence, at which point the VCR/CCNU chemotherapy protocol would be initiated.